Sign inSubscribe

target directory

anemia associated with chronic kidney disease in hemodialysis subjects clinical trial intelligence

Trials are included when the normalized target field matches this target directory. Full protocol, result, eligibility and IP analysis is available inside the premium workspace.

Validated reports

1

Directory type

target

Association rule

normalized field

NCT03461146
Source recordAI-normalized

A Phase III, Open-label Study of MT-6548 in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan

Tanabe Pharma Corporation conducted a Phase III trial of MT-6548, an oral tablet, to evaluate its efficacy and safety in hemodialysis patients with anemia not receiving erythropoiesis-stimulating agents (ESAs). The study enrolled 24 participants and aimed to assess hemoglobin (Hb) correction and maintenance.

AI analysis

Indication: Anemia; Hemodialysis Dependent Chronic Kidney Disease

Modality: small molecule

Target: Anemia associated with chronic kidney disease in hemodialysis subjects

Sponsor: Tanabe Pharma Corporation

Source URL: ClinicalTrials.gov

Source updated: Apr 06, 2026

Ingested: Jun 03, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by target_normalized: Anemia associated with chronic kidney disease in hemodialysis subjects

View original source fields

Condition raw: Anemia; Hemodialysis Dependent Chronic Kidney Disease

Condition normalized: Anemia; Hemodialysis Dependent Chronic Kidney Disease

Modality raw: Anemia; Hemodialysis Dependent Chronic Kidney Disease

Modality normalized: small molecule

Target raw: Anemia associated with chronic kidney disease in hemodialysis subjects

Target normalized: Anemia associated with chronic kidney disease in hemodialysis subjects

Open report